STOCK TITAN

Armistice Capital and Steven Boyd disclose 1.54M ANRO shares (4.94%)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Alto Neuroscience, Inc. — Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 1,536,000 shares, representing 4.94% of common stock as of 12/31/2025.

The filing states Armistice Capital exercises shared voting and dispositive power over the 1,536,000 shares held by Armistice Capital Master Fund Ltd., and that the Master Fund has the right to receive dividends or sale proceeds. The Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement; Mr. Boyd, as managing member, may be deemed to beneficially own the securities.

Positive

  • None.

Negative

  • None.

Insights

Armistice reports a sub-5% stake with shared voting and dispositive power.

Armistice Capital and Steven Boyd report beneficial ownership of 1,536,000 shares (4.94%) as of 12/31/2025, with shared voting and dispositive power over those shares held by the Master Fund. The filing attributes managerial control to Armistice under an Investment Management Agreement.

The Master Fund retains entitlement to dividends or sale proceeds per the filing, while disclaiming beneficial ownership because it lacks voting or dispositive authority. Subsequent filings could show changes if either holdings or voting arrangements change.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/18/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/18/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 18, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital hold in Alto Neuroscience (ANRO)?

Armistice Capital and Steven Boyd report beneficial ownership of 1,536,000 shares, equal to 4.94% of common stock as of 12/31/2025. The filing attributes shared voting and dispositive power over those shares.

Does Armistice Capital or the Master Fund control the shares?

The filing states Armistice Capital exercises voting and investment power over the shares held by Armistice Capital Master Fund Ltd., and thus may be deemed to beneficially own them; the Master Fund disclaims beneficial ownership due to lack of voting/dispositive authority.

What powers does Steven Boyd report over ANRO shares?

Steven Boyd, as managing member of Armistice Capital, is reported to have shared voting power and shared dispositive power over 1,536,000 shares, representing 4.94% as of 12/31/2025, per the joint filing.

Who receives dividends or sale proceeds for the reported shares?

The filing states the Armistice Capital Master Fund Ltd. has the right to receive dividends from, or proceeds from the sale of, the reported securities, as disclosed in Item 6 of the filing dated 02/18/2026.
Alto Neuroscienc

NYSE:ANRO

ANRO Rankings

ANRO Latest News

ANRO Latest SEC Filings

ANRO Stock Data

562.92M
26.83M
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW